Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice?
| العنوان: | Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? |
|---|---|
| المؤلفون: | Adilia Warris, Julia Del amo, Roberto CAUDA, Renato Alberto Finazzi, Aba Mahamat, Antonio Chiesi, Giuseppe Ippolito, Dominique Costagliola, Margaret May, Vicente Soriano, Michael John Gill, Fiona Lampe, Maria Jose Amengual, Patrizio Pezzotti, Matthias Egger, Jonathan Sterne, Huldrych Günthard, STEFANO VELLA, Alexandra Montoliu, Willem Melchers, Adrian Streinu-Cercel, Sophie Matheron, Michael Kozal, André Cabié, Terese L Katzenstein, Annalisa Saracino, Cedric Arvieux, Bart Rijnders, Elisa De Lazzari, Alicja Wiercińska-Drapało, Carmen Cabellos, Felipe García, Mariana Gerschenson |
| المساهمون: | University of Zurich, Mugavero, M J, Other departments, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Infectious diseases, General Internal Medicine, Graduate School, Global Health, Paediatric Infectious Diseases / Rheumatology / Immunology, Medical Microbiology and Infection Prevention, Antiretroviral Therapy Cohort, Collaboration, Mugavero, Mj, May, M, Harris, R, Saag, M, Costagliola, D, Egger, M, Phillips, A, Günthard, Hf, Dabis, F, Hogg, R, de Wolf, F, Fatkenheuer, G, Gill, Mj, Justice, A, D'Arminio Monforte, A, Lampe, F, Miró, Jm, Staszewski, S, Sterne, Ja, Piazza, Marcello, Nappa, Salvatore |
| المصدر: | Aids, 22, 18, pp. 2481-92 Aids, 22, 2481-92 Aids, 22(18), 2481-92. LIPPINCOTT WILLIAMS & WILKINS AIDS (London, England), 22(18), 2481-2492. Lippincott Williams and Wilkins |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, Infectious diseases and international health [NCEBP 13], Drug Resistance, HIV Infections, 10234 Clinic for Infectious Diseases, chemistry.chemical_compound, 0302 clinical medicine, Abacavir, virologic failure, Odds Ratio, Immunology and Allergy, Drug Interactions, 030212 general & internal medicine, Viral, 0303 health sciences, Lamivudine, virus diseases, Lopinavir, Middle Aged, Viral Load, 3. Good health, Pathogenesis and modulation of inflammation [N4i 1], Infectious Diseases, Treatment Outcome, Anti-Retroviral Agents, naïve patients, Combination, 2723 Immunology and Allergy, RNA, Viral, Reverse Transcriptase Inhibitors, Drug Therapy, Combination, Female, Functional Neurogenomics [DCN 2], Infection and autoimmunity [NCMLS 1], medicine.drug, Adult, medicine.medical_specialty, Efavirenz, Nevirapine, Adolescent, Immunology, 610 Medicine & health, Auto-immunity, transplantation and immunotherapy [N4i 4], Article, Disease-Free Survival, Invasive mycoses and compromised host [N4i 2], 03 medical and health sciences, Zidovudine, Young Adult, Drug Therapy, Internal medicine, Drug Resistance, Viral, medicine, Humans, 2403 Immunology, 030306 microbiology, business.industry, Poverty-related infectious diseases [N4i 3], 2725 Infectious Diseases, Nelfinavir, chemistry, 10036 Medical Clinic, HIV-1, RNA, Ritonavir, Microbial pathogenesis and host defense [UMCN 4.1], clinical event, business, Epidemiologic Methods, HIV. antiretroviral therapy |
| الوصف: | Contains fulltext : 70499.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naive patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States. STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naive HIV-positive patients initiating ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with a zidovudine and lamivudine nucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95% confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20, 95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48). CONCLUSION: Among antiretroviral-naive patients initiating therapy, between-ART regimen, differences in short-term virologic failure do not necessarily translate to differences in clinical outcomes. Our results should be interpreted with caution because of the possibility of residual confounding by indication. |
| وصف الملف: | application/pdf; Mugavero_AIDS_2008V.pdf - application/pdf; STAMPA |
| تدمد: | 0269-9370 1473-5571 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8483570ce499640ac5f34c66c49171f3Test https://hdl.handle.net/2066/70499Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8483570ce499640ac5f34c66c49171f3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 02699370 14735571 |
|---|